Commerce Bank purchased a new position in shares of Agilent Technologies, Inc. (NYSE:A – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 19,333 shares of the medical research company’s stock, valued at approximately $2,568,000.
Other hedge funds have also bought and sold shares of the company. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of Agilent Technologies by 4.3% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 599,581 shares of the medical research company’s stock valued at $82,712,000 after acquiring an additional 24,687 shares in the last quarter. Dudley & Shanley Inc. boosted its holdings in Agilent Technologies by 25.9% in the second quarter. Dudley & Shanley Inc. now owns 69,500 shares of the medical research company’s stock worth $9,232,000 after purchasing an additional 14,300 shares during the period. Crossmark Global Holdings Inc. increased its stake in Agilent Technologies by 39.6% during the fourth quarter. Crossmark Global Holdings Inc. now owns 33,918 shares of the medical research company’s stock valued at $4,615,000 after purchasing an additional 9,615 shares during the last quarter. Capricorn Fund Managers Ltd bought a new stake in Agilent Technologies during the first quarter valued at $8,161,000. Finally, BIP Wealth LLC acquired a new stake in shares of Agilent Technologies during the second quarter worth $834,000.
Agilent Technologies Price Performance
Shares of NYSE A opened at $153.37 on Tuesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 2.10 and a quick ratio of 1.62. The firm has a market capitalization of $43.32 billion, a PE ratio of 30.80, a P/E/G ratio of 2.80 and a beta of 1.25. Agilent Technologies, Inc. has a 1-year low of $108.35 and a 1-year high of $160.51. The business’s fifty day moving average price is $138.03 and its two-hundred day moving average price is $126.32.
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on A. Sanford C. Bernstein started coverage on shares of Agilent Technologies in a research report on Friday, June 26th. They issued an “outperform” rating and a $155.00 price target on the stock. Royal Bank Of Canada started coverage on shares of Agilent Technologies in a research report on Wednesday, May 27th. They set an “outperform” rating and a $153.00 price objective for the company. Robert W. Baird increased their price objective on shares of Agilent Technologies from $155.00 to $156.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 26th. Morgan Stanley raised their target price on shares of Agilent Technologies from $160.00 to $175.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Finally, Wolfe Research restated a “hold” rating on shares of Agilent Technologies in a research note on Tuesday, June 2nd. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $160.24.
View Our Latest Analysis on Agilent Technologies
Agilent Technologies Profile
Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.
Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.
Recommended Stories
- Five stocks we like better than Agilent Technologies
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A – Free Report).
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
